In conclusion, we suggest that circulating ITIH4 correlates with disease risk, disease activity, and treatment outcomes of RA; consequently, it can be used as a potential biomarker which helps clinicians to stratify RA patients, individualize their treatment, and improve the outcomes in RA patients. This evidence concerns the gene ITIH4 and rheumatoid arthritis.